Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)
Not Applicable
Recruiting
- Conditions
- Idiopathic pleuroparenchymal fibroelastosis
- Registration Number
- JPRN-UMIN000042946
- Lead Sponsor
- Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Have a history of treatment either with pirfenidone or nintedanib NAC, prednisone > 15 mg/day or equivalent, azathioprine, cyclosporine or cyclophosphamide received within 8 weeks of visit 1 Have airway obstruction Have lung cancer Have pulmonary hypertension Developed acute exacerbation within 3 months of visit 1 etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method %FVC decline rate during 26-week treatment of nintedanib versus the rate of baseline
- Secondary Outcome Measures
Name Time Method